Amgen Raises 2026 Revenue Outlook to $38.9 Billion to $39.7 Billion
Amgen raised its 2026 revenue forecast to $38.9B-$39.7B, up from prior guidance. Q3 revenue grew 8% to $10.4B. Non-GAAP EPS expected at $22.90-$23.70. Operating expenses may rise in Q4, according to the company.
How this was made
The 30-second read
Why it matters
A guidance raise typically leads traders to adjust forward estimates and risk premia for the stock, especially when both revenue and EPS ranges move higher.
Market read
Traders can update AMGN’s 2026 earnings expectations immediately based on the higher revenue and non-GAAP EPS ranges.
What to watch
The article mentions a meaningful sequential increase in Q4 operating expenses; if costs rise faster than revenue, the market may scrutinize margin sustainability despite higher full-year guidance.
Background
The piece is a company guidance update, citing both the raised full-year 2026 revenue and non-GAAP EPS ranges and Q3 revenue growth.
Ticker impact
Amgen raised its full-year 2026 revenue outlook to $38.9B-$39.7B and non-GAAP EPS to $22.90-$23.70, above prior guidance.
Likely upward pressure as the market reprices AMGN’s 2026 earnings power versus the prior guidance range.
The article reports a guidance raise with explicit ranges and notes both revenue and EPS are higher than the company’s previous outlook, which is typically supportive for valuation and estimates.
Market effects
Signals strength in large-cap biotech earnings expectations, which can modestly buoy sentiment across pharma/biotech peers with similar demand and cost dynamics.
Primarily impacts US large-cap biotech sentiment; limited direct spillover beyond healthcare sector positioning.
Could modestly influence global biotech risk appetite via improved outlook expectations, but the catalyst is company-specific.
Counterpoint
Guidance raises can reflect timing shifts (phasing of revenue/expenses) rather than durable improvement, so upside may fade if later quarters do not follow through.
Key entities
- companyAmgen
Raised full-year 2026 revenue and non-GAAP EPS outlook above prior guidance; reported Q3 revenue growth and expects higher sequential Q4 operating expenses.
